Floatz logo

VOLRUBIGENE RALAPARVOVEC

Crigler-Najjar Syndrome

Audentes Therapeuticsgene_therapyPhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Crigler-Najjar Syndrome cohort.

Asset / SponsorPhaseRating
Imlifidase
Genethon
Phase 2CCC
gnt0003
Genethon
Phase 2CCC
Orlistat
University Medical Center Groningen
N/AD
Hepastem
Cellaion SA
Phase 1/2NR

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →